| English | Español |
 |
 |
 |
 |
|
January 5, 2010
Clinical Trial Announcement
Study: Proton Radiation Therapy in Treating Patients With Prostate Cancer
Status: Recruiting
Sponsor: Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Link: Click Here
December 30, 2009
Clinical Trial Announcement
Study: Preoperative Radiation Therapy for High Risk Prostate Cancer
Status: Recruiting
Sponsor: Duke University
ClinicalTrials.gov Link: Click Here
December 24, 2009
Clinical Trial Announcement
Study: Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer
Status: Recruiting
Sponsor: University of Florida
ClinicalTrials.gov Link: Click Here
December 17, 2009
Clinical Trial Announcement
Study: Ketoconazole and Dexamethasone in Prostate Cancer (Keto/Dex)
Status: Recruiting
Sponsor: University of California, San Francisco
ClinicalTrials.gov Link: Click Here
December 11, 2009
Industry News
December 7, 2009
Clinical Trial Announcement
Study: MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate
Status: Recruiting
Sponsor: Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Link: Click Here
December 3, 2009
Clinical Trial Announcement
Study: Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
Status: Recruiting
Sponsor: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Link: Click Here
November 30, 2009
Clinical Trial Announcement
Study: Abiraterone Acetate, Prednisone, and Leuprolide Acetate Before and During Radiation Therapy in Treating Patients With Localized or Locally Advanced Prostate Cancer
Status: NOT YET Recruiting
Sponsor: Fred Hutchinson Cancer Research Center
ClinicalTrials.gov Link: Click Here
November 24, 2009
Clinical Trial Announcement
Study: Hormone Therapy With or Without Bevacizumab in Treating Patients With Recurrent Prostate Cancer
Status: NOT YET Recruiting
Sponsor: Cancer Institute of New Jersey
ClinicalTrials.gov Link: Click Here
November 19, 2009
Clinical Trial Announcement
Study: Abiraterone Acetate Plus Prednisone Drug-Drug Interaction With Dextromethorphan and Theophylline Treating Metastatic Castration-Resistant Prostate Cancer
Status: Recruiting
Sponsor: Cougar Biotechnology
ClinicalTrials.gov Link: Click Here
November 16, 2009
Industry News
Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
November 11, 2009
Breast Cancer Clinical Trial Results
Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
November 5, 2009
Breast Cancer Clinical Trial Announcement
Study: ABT-888 and Temozolomide for Metastatic Breast Cancer
Brief Description:
The purpose of this research study is to find out if the combination of ABT-888 and temozolomide is safe and effective in treating patients with metastatic breast cancer. ABT-888 works by obstructing a DNA enzyme called poly (ADP-ribose) polymerase (PARP) which helps repair cancer cells damaged by chemotherapy. By blocking the PARP enzyme, the cancer cells are unable to repair themselves and as a result die. The other drug in this study is temozolomide. Temozolomide is designed to damage DNA in order to prevent cancer cells from reproducing. Because PARP inhibitors, such as ABT-888, prevent cancer cells from repairing their own DNA, they enhance the potential of chemotherapy therapy like temozolomide to induce cell death. The combination of ABT-888 and temozolomide has been used in a clinical trial for treatment of other cancers and information for this research study suggests that the combination may help to inhibit growth in breast cancer.
Status: Recruiting
Sponsor: Massachusetts General Hospital
ClinicalTrials.gov Link: Click Here
November 4, 2009
Breast Cancer Clinical Trial Results
Three-Week Course of Breast Radiation May Be as Effective as Conventional Five to Seven Week Course for Early Breast Cancers, Says U.S. Study
CHICAGO, Nov. 4 /PRNewswire-USNewswire/ — According to a study presented November 4, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO), a shortened, more intensive course of radiation given to the whole breast, along with an extra dose of radiation given to the surgical bed of the tumor (concomitant boost), has been shown to result in excellent local control at a median follow up of two years after treatment with no significant side effects.
Industry News
Long-term Outcomes Data Validates the Utility of PROSTASCINT in Guiding Targeted Prostate Cancer Treatment and Predicting Disease Free Survival
November 3, 2009
Prostate Cancer Clinical Trial Results
Shorter Radiation Course as Effective as Standard Therapy For Prostate Cancer Recurrence
Prostate Cancer Clinical Trial Results
Shorter Radiation Course Stops Cancer Growth in High-Risk Prostate Cancer Patients
November 2, 2009
Clinical Trial Results
Additional, Specialized Radiation Not Necessary for Some Women After Mastectomy
CHICAGO, Nov. 2 /PRNewswire-USNewswire/ — After mastectomy, breast cancer patients who receive radiation treatment to the lymph nodes located behind the breast bone do not live longer than those who do not receive radiation to this hard-to-treat area, according to a randomized 10-year study presented at the plenary session, November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Breast Cancer Clinical Trial Results
Additional, Specialized Radiation Not Necessary for Some Women After Mastectomy
CHICAGO, Nov. 2 /PRNewswire-USNewswire/ — After mastectomy, breast cancer patients who receive radiation treatment to the lymph nodes located behind the breast bone do not live longer than those who do not receive radiation to this hard-to-treat area, according to a randomized 10-year study presented at the plenary session, November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Breast Cancer Clinical Trial Announcement
Study: Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer (BOLERO-3)
Brief Description:
This phase III, double-blind, placebo-controlled multinational study will assess the combination everolimus, vinorelbine, and trastuzumab compared to the combination vinorelbine and trastuzumab with respect to progressive-free survival and over survival in HER2/neu positive women with locally advanced or metastatic breast cancer who are resistant to trastuzumab and have been pre-treated with a taxane.
Status: Recruiting
Sponsor: Novartis Pharmaceuticals
ClinicalTrials.gov Link: Click Here
Industry News
Dendreon Completes Submission of Biologics License Application for PROVENGE
Prostate Cancer Clinical Trial Results
Adding Proton Therapy ‘Boost’ to X-Ray Radiation Therapy Reduces Prostate Cancer Recurrences
Prostate Cancer Clinical Trial Results
Short-Term Hormone Therapy Added to Radiation Increases Survival for Medium-Risk, But Not Low-Risk, Prostate Cancer Patients
October 30, 2009
Clinical Trial Results
|
Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
WOODCLIFF LAKE, N.J., Oct. 30 /PRNewswire/ — Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer. |
October 26, 2009
Breast Cancer Clinical Trial Announcement
Study: Nipple Sparing Mastectomy
Brief Description:
The purpose of this study is to observe the cosmetic outcomes, patient satisfaction, and complications after skin sparing mastectomy with preservation of the nipple areolar complex. These outcomes will be observed in patients with both known cancer diagnosis and in those with indications for prophylactic mastectomy. The cosmetic appearance and complications will be followed through several post operative visits throughout the duration of the study. This study is conducted in conjunction with the plastic and reconstructive surgeons who will be performing the breast reconstruction procedures. Patient satisfaction will be measured via survey format. In addition, local recurrence rates will be compared to patients undergoing traditional mastectomy
Status: Recruiting
Sponsor: Carolinas Healthcare System
ClinicalTrials.gov Link: Click Here
October 21, 2009
Clinical Trial Results
Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
TUSTIN, Calif., Oct. 21 /PRNewswire-FirstCall/ — Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHMD) today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer. Preliminary data at the end of the six planned treatment cycles in the Phase II study showed that 28 of 46, or 61%, of all patients enrolled in the trial achieved an objective tumor response according to RECIST criteria. This data compares favorably with data from a published study showing an objective tumor response rate of 41% in a similar patient population receiving the same dosing regimen of docetaxel administered as a single agent.
October 9, 2009
Breast Cancer Clinical Trial Announcement
Study: ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer
Brief Description:
The long-term objective of this research is to understand the molecular mechanisms of acquired endocrine resistance in breast cancer. Identifying these mechanisms is critical to the implementation of novel therapeutic strategies that can target and overcome altered gene networks involved in controlling breast cancer progression. While patients with tumors over expressing HER1, 2, or 3 have been shown to have reduced survival, patients with those tumors which overexpressed HER4 (erbB4) had increased survival (Witton 2003).
This is a non-randomized, single-arm, proof of principle trial. Selected are patients with advanced-stage breast cancer whose tumors are ER+, tamoxifen refractory. Histologically proven diagnosis of recurrent or metastatic breast cancer is advanced cancer for which there is no treatment available which would have a reasonable chance of cure. Treatment failure is defined as tumor progression after chemotherapy and tamoxifen therapy. Patients will be given five 30mg doses of HDAC inhibitor (LBH) over a period of two weeks. A dose will be taken on Days 1,3,5,8 and 10. Patients will have a diagnostic tumor biopsy prior to drug administration and a diagnostic biopsy within 48 hours (2 days) of the last dose. Primary endpoints are measured by biopsy of palpable tumor with immunohistochemical staining for ERBB4. Secondary end points include the evaluation of cell death, apoptosis, with immunohistochemical staining for DNA breaks by TUNEL assay.
Status: Recruiting
Sponsor: Tulane University Health Sciences Center
ClinicalTrials.gov Link: Click Here
October 7, 2009
Breast Cancer Clinical Trial Announcement
Study: A Study of LY573636 in Patients With Metastatic Breast Cancer
Brief Description: The primary purpose of this study is to determine the objective response rate (complete and partial response) for patients who receive LY573636 for metastatic breast cancer.
Status: Recruiting
Sponsor: Eli Lilly and Company
ClinicalTrials.gov Link: Click Here
October 6, 2009
Industry News
FDA Grants Additional Fast Track Designation for OGX-011 in Combination with First Line Chemotherapy
BOTHELL, WA, and VANCOUVER, Oct. 6 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that OGX-011, also known as custirsen sodium, received an additional Fast Track Designation from the U.S. Food & Drug Administration (FDA) for progressive metastatic prostate cancer in combination with first-line docetaxel treatment. OncoGenex had previously received Fast Track Designation for second-line docetaxel treatment with OGX-011 in combination with docetaxel for treatment of progressive metastatic prostate cancer following docetaxel.
October 1, 2009
Prostate Cancer Clinical Trial Results
Prostate Cancer Study Results Published on Patients Treated With CyberKnife Radiosurgery
Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today publication of results from a study of early stage prostate cancer patients treated with CyberKnife Radiosurgery. The study demonstrated that erectile function was preserved in 81 percent of patients at a median follow-up of two years. Published rates of erectile function preservation at two years for other commonly used prostate cancer treatments, such as open surgery and conventional radiation therapy, range from 50-70 percent.
September 30, 2009
Breast Cancer Clinical Trials Results
Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
WAYNE, N.J. and EMERYVILLE, Calif., Sept. 30 /PRNewswire-FirstCall/ — Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from a randomized, placebo-controlled Phase 2 trial sponsored by Northwestern University. The study, which evaluated Nexavar® (sorafenib) tablets in combination with the chemotherapeutic agent, paclitaxel, in patients with locally advanced or metastatic HER-2 negative breast cancer, demonstrated a positive trend towards improvement of progression-free survival in the treatment group (p-value=0.09). The safety and tolerability profile of the combination was consistent with the previous experience with each agent and no new toxicities were observed.
September 29, 2009
Prostate Cancer Clinical Trial Announcement
Study: A Study of the Safety and Efficacy of Single-agent CNTO 888 (an Anti CC-Chemokine Ligand 2 [CCL2]) in Patients With Metastatic Prostate Cancer
Brief Description: The purpose of this study is to determine the safety and effectiveness of the study drug CNTO 888 in patients with metastatic castrate-resistant prostate cancer.
Status: Recruiting
Sponsor: Centocor, Inc.
ClinicalTrials.gov Link: Click Here
Breast Cancer Clinical Trial Announcement
Study: Vaccine Therapy in Treating Women With Triple-Negative Breast Cancer
Brief Description: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer. This clinical trial is studying the side effects and how well vaccine therapy works in treating women with triple-negative breast cancer.
Status: Recruiting
Sponsor: Case Comprehensive Cancer Center
ClinicalTrials.gov Link: Click Here
September 23, 2009
Industry News
Capecitabine Added to Standard Treatment Given Before Surgery Helps to Eradicate Tumours in Patients With Early Breast Cancer
Industry News
Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study
September 22, 2009
Breast Cancer Clinical Trials Results
Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
September 11, 2009
Breast Cancer Clinical Trial Announcement
Study: Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer
Brief Description: This research study hopes to examine the effects of Coenzyme Q10 on doxorubicin (Adriamycin) metabolism during breast cancer treatment. Doxorubicin is a lifesaving breast cancer treatment. However, approximately 320% of women who receive doxorubicin treatment experience some damage to their heart muscle. Coenzyme Q10 is a fat soluble antioxidant dietary supplement that may protect against this heart damage during doxorubicin treatment. It is unknown how Coenzyme Q10 may interact with doxorubicin. This study will assess the effects of Coenzyme Q10 on doxorubicin metabolism.
Status: Recruiting
Sponsor: Columbia University
ClinicalTrials.gov Link: Click Here
September 10, 2009
Industry News
Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer
Industry News
September 9, 2009
Prostate Cancer Clinical Trial Announcement
Study: Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM)
Brief Description: This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy
Status: Recruiting
Sponsor: Medivation, Inc.
ClinicalTrials.gov Link: Click Here
September 3, 2009
Breast Cancer Clinical Trial Announcement
Study: Study to Evaluate Surgical Excision Margins in Malignant Breast Lumpectomies With the PEAK PlasmaBlade
Brief Description: The purpose of this research study is to find out more about distinguishing between cancerous and non-cancerous breast cancer cells at the edges of tumors. Using an FDA approved device to remove tumors, this device will be tested to see if it causes less tissue damage and therefore makes it easier to examine the tumor and make sure it is all excised. The tumors will be excised by standard surgical technique, and then the effects of the device on the removed tissues will be studied.
Status: Recruiting
Sponsor: University of California, San Diego
ClinicalTrials.gov Link: Click Here
September 1, 2009
Industry News
Prostate Cancer Clinical Trial Announcement
Study: Stereotactic Hypofractionated Radiosurgery for Early Stage Prostate Cancer
Brief Description: The purpose of this trial is to evaluate a short course of very focused (stereotactic) external beam radiation therapy for the treatment of early stage prostate cancer. The investigators will gather scientific information about the tolerance and side effects this type of radiation. The investigators will then compare these results with those of standard 8 week course of external beam radiation therapy to see if this study treatment is equally or more effective in treating prostate cancer.
Status: Recruiting
Sponsor: San Diego Radiosurgery
ClinicalTrials.gov Link: Click Here
Prostate Cancer Clinical Trial Announcement
Study: Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy (PR06)
Brief Description: Patients are being asked to take part in this study because they had prostate cancer that was treated surgically and it has been determined that they might have a greater risk of their prostate cancer returning or their prostate cancer has already returned. The purpose of this study is to see what effects, good and/or bad, image guided proton based radiation therapy, and/or conventional radiation therapy and hormonal therapy (if applicable), has on the patient’s prostate cancer that has already returned or the risk of their prostate cancer returning. With the patient’s consent, this study will also look at their prostate cancer tissue that was removed during their surgery for information that may help to treat prostate cancer in the future.
Status: Recruiting
Sponsor: University of Florida
ClinicalTrials.gov Link: Click Here
Prostate Cancer Clinical Trial Results
August 27, 2009
Industry News
August 24, 2009
Advocacy/Support
August 20, 2009
Advocacy/Support
August 19, 2009
Industry News
August 11, 2009
Breast Cancer Clinical Trial Announcement
Study: Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer
Brief Description: The purpose of this trial is to determine the efficacy and safety profile of TKI258 in 4 groups of patients with metastatic HER2 negative breast cancer (BC) stratified by FGFR1 and hormone receptor (HR) status
Status: Recruiting
Sponsor: Novartis
ClinicalTrials.gov Link: Click Here
August 4, 2009
Industry News
Industry News
July 29, 2009
Prostate Cancer Clinical Trial Announcement
Study: Active Surveillance for Cancer of the Prostate (ASCaP)
Brief Description: Active Surveillance (A.S.) of prostate cancer (CaP) is the systematic monitoring of men with low-risk, localized lesions, with curative treatment of those whose tumors show substantial progression. A.S. is different from Watchful Waiting (W.W.), which is the palliative treatment of men with progressive prostate cancer.
Status: Recruiting
Sponsor: University of California, Los Angeles
ClinicalTrials.gov Link: Click Here
July 28, 2009
Industry News
July 24, 2009
Prostate Cancer Clinical Trial Announcement
Study: Study Using WST11 In Patients With Localized Prostate Cancer (PCM202)
Brief Description: The aim of this study is to determine the optimal treatment conditions (WST11 dose and light energy dose) to achieve ablation in one lobe of the prostate and to evaluate the safety and quality of life of WST11 medicated Vascular-Targeted Photodynamic therapy (VTP) in men with localized prostate cancer.
Status: Recruiting
Sponsor: Steba Biotech S.A.
ClinicalTrials.gov Link: Click Here
July 22, 2009
Industry News
Prostate Cancer Clinical Trial Announcement
Study: Pazopanib as Second Line Therapy in Patients With Prostate Cancer Refractory to Total Androgen Blockade
Status: Recruiting
Sponsor: Illinois CancerCare, P.C.
ClinicalTrials.gov Link: Click Here
June 19, 2009
Advocacy/Support
Soccer Hall of Famer Marcelo Balboa Encourages Men to ‘Team Up Against Prostate Cancer’
June 17, 2009
Prostate Cancer Clinical Trial Announcement
Study: Phase I/II Study of Sorafenib Concurrent With Androgen Deprivation and Radiotherapy in the Treatment of Intermediate- and High-Risk Localized Prostate Cancer
Status: Recruiting
Sponsor: Beth Israel Medical Center
ClinicalTrials.gov Link: Click Here
Prostate Cancer Clinical Trial Announcement
Study: Neoadjuvant Abiraterone Acetate plus leuprolide acetate in men with localized high risk prostate cancer
Status: Not yet recruiting*
Anticipated start or recruitment: July 2009
Sponsor: Cougar Biotechnology
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the “subscribe” link at the top of the page.
June 11, 2009
Prostate Cancer Clinical Trial Announcement
Study: Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer PatientsStatus: Recruiting
Status: Recruiting
Sponsor: Oncology Specialists, S.C., Wyeth
ClinicalTrials.gov Link: Click Here
Prostate Cancer Clinical Trial Announcement
Study: Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg (CAMON)
Status: Recruiting
Sponsor: AstraZeneca
ClinicalTrials.gov Link: Click Here
June 9, 2009
Prostate Cancer Clinical Trial Announcement
Study: Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-Resistant Prostate Cancer
Status: Recruiting
Sponsor: Weill Medical College of Cornell University
ClinicalTrials.gov Link: Click Here
June 8, 2009
Prostate Cancer Clinical Trial Announcement
Study: Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)Status: Recruiting
Status: Not yet recruiting*
Anticipated start of recruitment: Unknown
Sponsor: Sanofi-Aventis
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
June 5, 2009
Prostate Cancer Clinical Trial Announcement
Study: Hypothermic Nerve Sparing Radical Prostatectomy
Status: Recruiting (by invitation)
Sponsor: University of California, Irvine
ClinicalTrials.gov Link: Click Here
June 2, 2009
Industry News
Medivation announces positive new efficacy data from Phase 1-2 trial of MDV3100 in advanced prostate cancer patients
June 1, 2009
Prostate Cancer Clinical Trial Announcement
Study: Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer
Status: Recruiting
Sponsor: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Link: Click Here
Prostate Cancer Clinical Trial Announcement
Study: QT/QTc and Multi-Dose Pharmacokinetic (PK) Study of Abiraterone Acetate
Status: Recruiting
Sponsor: Cougar Biotechnology
ClinicalTrials.gov Link: Click Here
Industry News
Ascenta Therapeutics announces presentation of promising results from clinical trials of AT-101 in prostate, brain, and lung cancers at 2009 ASCO annual meeting
Industry News
AEtna Zentaris presents data supporting evaluation of AEZS-108 in prostate cancer at ASCO meeting
Industry News
PROSTVAC data presented at ASCO meeting demonstrates the potential for significant increases in life expectancy in late-state prostate cancer
May 30, 2009
Industry News
OncoGenex Pharmaceuticals announces OGX-011 treatment provides survival benefit in randomized Phase 2 trial in advanced metastatic prostate cancer
May 28, 2009
Industry News
May 26, 2009
Prostate Cancer Clinical Trial Announcement
Study: GM-CSF in Treating Patients With Relapsed Prostate Cancer
Status: Not yet recruiting*
Anticipated start of recruitment: Unknown
Sponsor: The Cleveland Clinic, National Cancer Institute (NCI)
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
Prostate Cancer Clinical Trial Announcement
Study: Vaccine Therapy in Treating Patients With Progressive Stage D0 Prostate Cancer
Status: Recruiting
Sponsor: National Cancer Institute (NCI)
ClinicalTrials.gov Link: Click Here
May 22, 2009
Prostate Cancer Clinical Trial Announcement
Study: RNActive®-Derived Therapeutic Vaccine
Status: Recruiting
Sponsor: University of Florida, CureVac GmbH
ClinicalTrials.gov Link: Click Here
May 7, 2009
Prostate Cancer Clinical Trial Announcement
Study: Multicenter, Open Label, Phase 2 Study of Sipuleucel-T in Men with Metastatic Castrate Resistant Prostate Cancer (CRPC)
Status: Not yet recruiting*
Anticipated start of recruitment: August 2009
Sponsor: Dendreon
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
May 6, 2009
Advocacy/Support
Team ZERO to Run to End Prostate Cancer in 2009 ING New York City Marathon:
May 5, 2009
CTAG News
Clinical Trials Advocacy Group for Prostate Cancer partners with “Prostate Cancer InfoLink”
Prostate Cancer InfoLink “offering the most user-friendly personalized prostate cancer information on the web” has agreed to feature CTAG for Prostate Cancer as its default search tool for prostate cancer clinical trials.
To view the Prostate Cancer InfoLink webpage Click Here
April 28, 2009
Industry News
OncoGenex receives confirmation from FDA on the design of a second Phase 3 trial evaluating OGX-011 for the treatment of advanced prostate cancer:
Industry News
Data presented at AUA demonstrate PROVENGE significantly prolongs survival for men with advanced prostate cancer in pivotal Phase 3 IMPACT study:
April 27, 2009
Industry News
Ferring Pharmaceuticals launches Phase IIIB trial of Degarelix as intermittent therapy:
April 24, 2009
Prostate Cancer Clinical Trial Announcement
Study: Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy
Status: Not yet recruiting*
Anticipated start of recruitment: March 2009
Sponsor: Barbara Ann Karmanos Cancer Institute
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
April 23, 2009
Prostate Cancer Clinical Trial Announcement
Study: Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
Status: Not yet recruiting*
Anticipated start of recruitment: July 2009
Sponsor: Duke University
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
Prostate Cancer Clinical Trial Announcement
Study: A Two-Dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy
Status: Not yet recruiting*
Anticipated start of recruitment: Unknown
Sponsor: Johns Hopkins University
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
April 18, 2009
Prostate Cancer Clinical Trial Announcement
Study: Abiraterone Acetate in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer
Status: Not yet recruiting*
Anticipated start or recruitment: April 2009
Sponsor: Cougar Biotechnology
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
April 17, 2009
Prostate Cancer Clinical Trial Announcement
Study: Investigation of the effect of Degarelix in terms of prostate volume reduction in prostate cancer patients
Status: Not yet recruiting*
Anticipated start of recruitment: May 2009
Sponsor: Ferring Pharmaceuticals
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
March 31, 2009
Industry News
Stanford study on CyberKnife Radiosurgery for prostate cancer demonstrates 100 percent PSA response at 33 months:
 |
|
© Accrual Solutions 2009